Y-mAbs Therapeutics (NASDAQ:YMAB) Cut to Underperform at Bank of America

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) was downgraded by equities researchers at Bank of America from a "neutral" rating to an "underperform" rating in a report released on Tuesday, MarketBeat.com reports. They currently have a $3.00 price target on the stock. Bank of America's target price would indicate a potential downside of 26.83% from the stock's current price.

Other research analysts have also issued reports about the stock. Wedbush reiterated an "outperform" rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Morgan Stanley dropped their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research note on Wednesday, March 5th. Truist Financial decreased their target price on Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. Finally, HC Wainwright cut their price target on Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating for the company in a report on Friday, March 21st. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.40.

Y-mAbs Therapeutics Trading Down 0.7 %

Y-mAbs Therapeutics stock traded down $0.03 during mid-day trading on Tuesday, hitting $4.10. 108,610 shares of the company's stock were exchanged, compared to its average volume of 328,273. Y-mAbs Therapeutics has a 1-year low of $3.84 and a 1-year high of $17.78. The stock has a 50 day moving average of $4.87 and a two-hundred day moving average of $8.15. The stock has a market cap of $185.39 million, a P/E ratio of -7.59 and a beta of 0.71.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. During the same period in the prior year, the company posted ($0.02) EPS. As a group, research analysts predict that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Insider Activity

In other news, insider Thomas Gad sold 10,810 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares of the company's stock, valued at $1,060,230.83. The trade was a 5.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 22.50% of the company's stock.

Institutional Trading of Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Principal Financial Group Inc. raised its holdings in Y-mAbs Therapeutics by 9.4% during the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock worth $174,000 after purchasing an additional 1,903 shares during the last quarter. Rhumbline Advisers boosted its stake in Y-mAbs Therapeutics by 4.8% in the first quarter. Rhumbline Advisers now owns 53,909 shares of the company's stock valued at $239,000 after acquiring an additional 2,457 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Y-mAbs Therapeutics by 12.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,818 shares of the company's stock worth $179,000 after acquiring an additional 2,545 shares during the period. JPMorgan Chase & Co. raised its position in shares of Y-mAbs Therapeutics by 10.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company's stock valued at $399,000 after acquiring an additional 2,854 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock worth $139,000 after purchasing an additional 4,163 shares during the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.